CSIMarket Company Name, Ticker, Suppliers, else..
 
Fennec Pharmaceuticals Inc   (NASDAQ: FENC)
 
Price: $12.0300 $-0.32 -2.591%
Day's High: $12.419899940490723 Week Perf: -1.15 %
Day's Low: $ 11.88 30 Day Perf: 25.44 %
Volume (M): 348,050 52 Wk High: $ 13.25
Volume (M$): $ 0 52 Wk Avg: $8.61
Open: $12.35 52 Wk Low: $5.65



 Market Capitalization (Millions $) 428
 Shares Outstanding (Millions) 36
 Employees 35
 Revenues (TTM) (Millions $) 51
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company develops and commercializes PEDMARK®, a sodium thiosulfate injection product, and holds related patents. It manages patent litigation and licensing to protect its intellectual property and market exclusivity, including actions against generic competitors such as CIPLA.


   Company Address: PO Box 13628, 68 TW Alexander Drive Research Triangle Park 27709 NC
   Company Phone Number: 636-4530   Stock Exchange / Ticker: NASDAQ FENC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -0.93%    
OCGN   -5%    
PALI   -5.31%    
COLL   -12.63%    
CTXR   -5.78%    
PFE   -0.07%    
• View Complete Report
   



Clinical Study

Evolving Pediatric Care Fennec Pharmaceuticals Pedmarqsi Gains NICE Green Light to Combat Cisplatin-Induced H...

Published Fri, Dec 20 2024 11:16 AM UTC

In a significant advancement in pediatric healthcare, Fennec Pharmaceuticals has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its groundbreaking treatment, Pedmarqsi (anhydrous sodium thiosulfate). This marks a pivotal moment for children and young adults, aged between one month and 17 years, who are subjected to th...
Management Changes

Fennec Pharmaceuticals Appoints Industry Leader Jeffrey S. Hackman as CEO to Drive Commercial Success and Spearhead Oncology Innovations

Published Mon, Aug 5 2024 10:26 AM UTC

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
Fennec Pharmaceuticals Inc, a leading biopharmaceutical company focused on the development of innovative oncology treatments, has recently announced the appointment of Jeffrey S. Hackman...
Licensing Agreement

Fennec Pharmaceuticals' Strategic Licensing Deal with Norgine Marks a Milestone for Pediatric Cancer Treatment

Published Mon, Mar 18 2024 1:00 AM UTC

Fennec Pharmaceuticals, a renowned pharmaceutical company specializing in the development of innovative therapies for cancer treatment, has recently entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. This groundbreaking partnership combines Norgine s commercial expertise and extensive European footprin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 8.39
Price to Sales (Expected) -
Price to Book 11.35
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.61
Working Capital Ratio 11.46
Leverage Ratio (MRQ) 0.91
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -340.82 $
Revenues (TTM) 1.43 $
Cash Flow (TTM) 0.49 $
Cash 2.26 $
Book Value 1.06 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,457,114
Net Income per Employee (TTM) -239,286
Receivable Turnover Ratio (TTM) 2.59
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.56

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -0.79 %
Net Margin (MRQ) 1.33 %
Net Cash Flow Margin (MRQ) 22.45 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Fennec Pharmaceuticals Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.